

Transforming Breast Cancer Detection with AI

Sivan Sadan: Sivan Sadan

“From Detection to Prediction: Diagnosing Disease Before Symptoms.” •

Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Pink Star develops AI for breast MRI to help radiologists detect cancer earlier and more accurately. Partnering with Sheba Medical Center, it trains advanced models for automated lesion detection, enabling earlier diagnosis and reducing unnecessary biopsies. Led by a multidisciplinary team, the company has raised initial funding and is finalizing a data collaboration with a leading U.S. medical center. • **Core Technology:** What is the technology, its uniqueness, and its value proposition? Pink Star's core technology is an advanced AI technology for breast MRI, trained on uniquely curated, high-quality clinical datasets from Sheba Medical Center. The decision support software will assist radiologists, enhancing diagnostic accuracy, enabling earlier cancer detection, and reducing unnecessary biopsies. Its value proposition: better outcomes for women, greater efficiency for providers, and lower costs for payors. • **Product Profile/Pipeline:** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Pink Star is currently developing its breast MRI AI solution and is in the final stages of signing a data agreement with a leading U.S. medical center. Following product completion, the company plans to pursue FDA clearance and initiate commercialization through its design partner. Long term, Pink Star aims to integrate with leading enterprise AI imaging platforms • **Business Strategy:** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. Pink Star will deploy its breast MRI AI as a clinical decision-support solution integrated into radiology workflows. Short term, revenue will be generated through deployments and commercial agreements with design partners and early-adopter medical centers or imaging centers. Long term, the company will scale via FDA clearance, enterprise licensing, and strategic integrations with leading imaging AI platforms. • **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Next,** Pink Star will complete product development and conduct validation studies using clinical data from U.S. and Israeli partners. Following FDA submission, the company will expand its team across technology, clinical, and commercial functions. Financial plans include leveraging initial funding to finalize development, support regulatory approval, and prepare for market launch through early partnerships and long-term enterprise integrations